在GEMINI-1/-2和STAT试验中，病毒载量高的成人患者起始使用多替拉韦/拉米夫定的疗效和安全性结果。
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.
作者信息
Rolle Charlotte-Paige, Arribas José R, Ortiz Roberto, Underwood Mark, Parry Chris M, Grove Richard, DiMondi V Paul, Jones Bryn, Kisare Michelle
机构信息
Orlando Immunology Center, Orlando, Florida, USA.
Department of Internal Medicine, La Paz University Hospital, Hospital La Paz Institute for Health Research, Biomedical Research Networking Center for Infectious Diseases, Madrid, Spain.
出版信息
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf135. doi: 10.1093/ofid/ofaf135. eCollection 2025 Mar.
Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL). NCT02831673/NCT02831764; NCT03945981.
在GEMINI-1/2研究中观察了144周，在STAT研究中观察了48周，多替拉韦/拉米夫定在初治抗逆转录病毒治疗的个体中，无论基线病毒载量类别如何，包括基线病毒载量非常高（≥500 000拷贝/毫升）的个体，均显示出高病毒学疗效和良好的安全性。NCT02831673/NCT02831764；NCT03945981。
Zotero 插件